Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jan 21;17(1):e1003023.
doi: 10.1371/journal.pmed.1003023. eCollection 2020 Jan.

Isoniazid-resistant tuberculosis: A problem we can no longer ignore

Giorgia Sulis  1   2 , Madhukar Pai  1   2   3
Affiliations
Comment

Isoniazid-resistant tuberculosis: A problem we can no longer ignore

Giorgia Sulis et al. PLoS Med. .

Abstract

Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis.

PubMed Disclaimer

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: MP serves on the editorial boards of PLoS Medicine and PLoS One, and is a co-editor of the PLOS Tuberculosis Channel. He has no financial or industry interests to disclose.

Comment on

References

    1. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update. Geneva: World Health Organization (WHO); 2013. - PubMed
    1. Kendall EA, Sahu S, Pai M, Fox GJ, Varaine F, Cox H, et al. What will it take to eliminate drug-resistant tuberculosis? Int J Tuberc Lung Dis. 2019;23(5):535–46. Epub 2019/05/18. 10.5588/ijtld.18.0217 - DOI - PMC - PubMed
    1. Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1): e1003008 10.1371/journal.pmed.1003008. - DOI - PMC - PubMed
    1. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):223–34. 10.1016/S1473-3099(16)30407-8 . - DOI - PubMed
    1. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization (WHO); 2018. - PubMed